Dechra Pharmaceuticals (LON:DPH) had its price target reduced by HSBC from GBX 2,770 ($36.19) to GBX 2,700 ($35.28) in a research note issued to investors on Monday. They currently have a buy rating on the stock.
Separately, Royal Bank of Canada decreased their target price on Dechra Pharmaceuticals from GBX 2,400 ($31.36) to GBX 2,100 ($27.44) and set a sector performer rating for the company in a research note on Friday, November 23rd.
Shares of DPH stock opened at GBX 2,457.26 ($32.11) on Monday. The company has a debt-to-equity ratio of 62.79, a current ratio of 2.51 and a quick ratio of 1.58. Dechra Pharmaceuticals has a 52 week low of GBX 1,992 ($26.03) and a 52 week high of GBX 3,180 ($41.55). The company has a market capitalization of $2.52 billion and a price-to-earnings ratio of 101.54.
In related news, insider Tony Griffin bought 5,000 shares of the firm’s stock in a transaction on Tuesday, December 18th. The stock was bought at an average cost of GBX 2,115 ($27.64) per share, for a total transaction of £105,750 ($138,181.11).
Dechra Pharmaceuticals Company Profile
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.